Provectus Biopharmaceuticals Inc (PVCT)

[Paulness]

Independent Contributions Account for Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies
Emmett Schmidt, PhD, Distinguished Scientist & Executive Director, Merck Research Labs

Clinical combination studies including PD-1 checkpoint inhibitors exploded in the 7 years since the first PD-1 checkpoint inhibitor approvals. Expectations of combination success were high at first. Seven years on, it is important to assess these studies more realistically. The presenter recently published a cross sectional study of PD-1 pathway checkpoint inhibitor clinical trials. Encouraging and discouraging results will be reviewed to guide thinking about future combination strategies.